Economic analysis of epoetin alfa in critically ill trauma patients

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 1, 2012, Pages 195-201

  Chui, Betty K ^a   Pannu, Neesh ^a   Hazel, Maureen ^a   Dong, James ^a   Tonelli, Marcello ^a   Klarenbach, Scott W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Erythropoietin; recombinant; cost benefit analysis; critical care.

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; CRITICAL ILLNESS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOSIS;

COST-BENEFIT ANALYSIS; CRITICAL ILLNESS; DRUG COSTS; ERYTHROPOIETIN; HUMANS; INTENSIVE CARE; MODELS, ECONOMETRIC; MONTE CARLO METHOD; RECOMBINANT PROTEINS; RISK;

EID: 84864212948     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e31824ba1da     Document Type: Article

References (27)

1. Walsh TS, Wyncoll DL, Stanworth SJ. Managing anaemia in critically ill adults. BMJ. 2010;341:c4408.
2. Shander A Anemia in the critically ill. Crit Care Clin. 2004;20:159-178
3. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietinreceptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ. 2007;177:725-734.
4. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288:2827-2835.
5. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965-976.
6. Napolitano LM, Fabian TC, Kelly KM, et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma. 2008;65:285-297; discussion 297-289.
7. Velmahos GC. Erythropoiesis and the mystery of an unexplained survival benefit. Ann Surg. 2010;251:5.
8. Nathens AB, Rivara FP, MacKenzie EJ, et al. The impact of an intensivistmodel ICU on trauma-related mortality. Ann Surg. 2006;244:545-554.
9. Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. PLoS Med. 2009;6:e1000098.
10. Korosec Jagodic H, Jagodic K, Podbregar M. Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma. Crit Care. 2006;10:R134.
11. Alberta Health and Wellness Drug Benefits List. 2010. Available at: https://www.ab.bluecross.ca/dbl/idbl-main1.html. Accessed March 28, 2011.
12. Klarenbach SW, Pannu N, Tonelli MA, Manns BJ. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care Med. 2006;34:1044-1051.
13. Noseworthy TW, Konopad E, Shustack A, Johnston R, Grace M. Cost accounting of adult intensive care: methods and human and capital inputs. Crit Care Med. 1996;24:1168-1172.
14. Amin M, Fergusson D, Wilson K, et al. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion. 2004;44:1479-1486.
15. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res. 2003;3:7.
16. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deepvein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm. 2006;63(20 suppl 6):S5YS15.
17. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies. 3rd ed. Ottawa, Canada: Canadian Agency for Drugs and Technologies in HealthVAgence canadienne des médicaments et des technologies de la santé; 2006.
18. Bank of Canada Rates and Statistics. 2011. Available at: http://www.bankbanque- canada.ca/en/rates/inflation-calc.html. Accessed March 28, 2011.
19. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290-308.
20. Life Tables, Canada, Provinces and Territories, 2000 to 2002. 2006. Available at: http://www.statcan.gc.ca/bsolc/olc-cel/olc-cel?catno-84-537- X&CHROPG-1&lang-eng. Accessed August 1, 2010.
21. Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008;11:771-783.
22. Shermock KM, Horn E, Lipsett PA, Pronovost PJ, Dorman T. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med. 2005;33:497-503.
23. MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health. 2005;8:105-116.
24. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, doubleblind, placebo-controlled trial. Crit Care Med. 1999;27: 2346-2350.
25. Nichol AD, Cooper DJ. Can we improve neurological outcomes in severe traumatic brain injury? Something old (early prophylactic hypothermia) and something new (erythropoietin). Injury. 2009;40:471-478.
26. Talving P, Lustenberger T, Kobayashi L, et al. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg. 2010;251:1-4.
27. Davidson GH, Hamlat CA, Rivara FP, Koepsell TD, Jurkovich GJ, Arbabi S. Long-term survival of adult trauma patients. JAMA. 2011;305: 1001-1007.